TNF Receptor-Associated Periodic Syndrome - TRAPS
TNF receptor-associated periodic syndrome (TRAPS) is a rare inherited autoinflammatory disorder caused by mutations in the TNFRSF1A gene. The mutation disrupts the receptor for tumor necrosis factor (TNF), leaving the immune system in a constant state of overactivation and triggering long, painful bouts of inflammation.
At Haute-Derma, we recognize TRAPS as the inherited autoinflammatory syndrome with the longest-lasting flares. Using modern targeted biologic therapies, we focus on switching off inflammation at the molecular level, protecting your internal organs and giving you back a life no longer interrupted by prolonged episodes of pain.
Our Approach to Treating TRAPS
Our specialists at Haute-Derma take a comprehensive approach to TRAPS that combines control of acute symptoms with long-term prevention of complications. We understand that TRAPS flares can last for weeks, leaving patients exhausted and seriously disrupting daily life.
We were early adopters of new-generation anti-cytokine biologics, which not only bring fevers down quickly but also help prevent amyloid deposits in the kidneys, the most serious threat to people with TRAPS. At Haute-Derma, your treatment plan is tailored to you to achieve the most durable remission possible.
Our TRAPS care pathway includes:
- TNFRSF1A gene sequencing to identify the exact variant.
- Biologic therapy targeting TNF or IL-1, depending on each patient's response.
- Multidisciplinary follow-up (eyes, kidneys, joints) to keep systemic features under control.
How We Diagnose TRAPS at Haute-Derma
Because TRAPS can present in many different ways, Haute-Derma follows a rigorous diagnostic process to distinguish it from other autoinflammatory syndromes:
- Assessing flare duration: the key clue is prolonged fever episodes, usually lasting more than 7 days and sometimes several weeks.
- Recognizing the typical skin lesions: painful red patches that tend to travel down the limbs (centrifugal migration).
- Checking for eye involvement: looking for periorbital edema, a finding that strongly suggests TRAPS.
- Measuring systemic inflammatory markers: tracking the sharp, sustained rise in CRP and erythrocyte sedimentation rate (ESR) throughout a flare.
- Molecular genetic analysis: identifying a TNFRSF1A mutation to confirm the diagnosis and provide genetic counseling for the family.
How the Condition Is Treated at Haute-Derma
Our treatment protocol aims to neutralize excess inflammatory signals and stabilize TNF receptor activity:
- Interleukin-1 (IL-1) blockade: drugs such as canakinumab are now our first choice for TRAPS at Haute-Derma, as they control inflammation very effectively and are safer than high-dose corticosteroids.
- TNF inhibition (etanercept): in selected cases, this treatment replaces the missing soluble TNF receptors and noticeably reduces the severity of flares.
- Targeted management of muscle and joint pain: nonsteroidal anti-inflammatory drugs (NSAIDs) are added to ease the deep muscle pain (myalgia) typical of TRAPS.
- Screening for and preventing amyloidosis: regular serum amyloid A (SAA) checks to keep inflammation within a range that is safe for the kidneys.
- Personalized activity and psychological support: guidance on gentle exercise and stress management techniques to avoid triggering new flares.
